OBO_ID (LABEL):	CHEBI_28934 (vitamin D2)

IGNORANCE CATEGORY:	future_work

ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
PMC3356951	4/2012	S9-PMC3356951	['treatment with either Vitamin D2 or Vitamin D3 is RECOMMENDED for deficient patients.']	[('FUTURE_WORK', 50)]	1	[('CHEBI_28934', 'vitamin D2', 22, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 22, 'vitamin D2'), ('CHEBI_33279', 'vitamin D5', 36, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 36, 'vitamin D3')]
PMC4600246	10/2015	S69-PMC4600246	['the mechanisms responsible include (1) activation of growth-inhibiting proteins requiring Vitamin K2, such as prothrombin,62(2) Arylation pathways,63(3) activation of growth arrest Genes such as gas 6,64and (4) and increased C-Jun and C-Myc mrna Expression in Hepatoma Cells.57\npreventing the Recurrence of hcc is an IMPORTANT STRATEGY, ESPECIALLY CONSIDERING the fact that EVEN after patients undergo curative therapy recurrence rates REMAIN high.65while triple combination therapy with Boceprevir or Telaprevir, pegylated interferon (ifn) and Ribavirin is effective for the treatment of hepatitis c virus (Hcv), INFORMATION on preventing hcc development and/or recurrence as well as all-cause mortality is LACKING.6667moreover, this combination therapy is expensive, REQUIRES injections (ifn) and is OFTEN not well tolerated DUE TO adverse events (ie, fever and pancytopenia).']	[('IMPORTANT_CONSIDERATION', 317), ('FUTURE_WORK', 327), ('IMPORTANT_CONSIDERATION', 337), ('IMPORTANT_CONSIDERATION', 348), ('ANOMALY_CURIOUS_FINDING', 374), ('INCOMPLETE_EVIDENCE', 436), ('INCOMPLETE_EVIDENCE', 614), ('FULL_UNKNOWN', 708), ('INCOMPLETE_EVIDENCE', 708), ('IMPORTANT_CONSIDERATION', 769), ('PROBABLE_UNDERSTANDING', 802), ('PROBLEM_COMPLICATION', 827)]	12	[('CHEBI_28934', 'vitamin D2', 90, 'vitamin K2'), ('PR_000017299', 'VIP peptides', 90, 'vitamin K2'), ('GO_0006915', 'apoptotic process', 128, 'arylation'), ('SO_0000704', 'gene', 181, 'genes'), ('PR_000004968', 'calretinin', 225, 'c-Jun'), ('PR_000000084', 'c-myc protein', 235, 'c-Myc'), ('GO_0010467', 'gene expression', 246, 'expression'), ('CL_0000632', 'hepatic stellate cell', 260, 'hepatoma cells'), ('GO_0000003', 'reproduction', 293, 'recurrence'), ('CHEBI_68621', 'boceprevir', 488, 'boceprevir'), ('CHEBI_68593', 'eurysterol B(1-)', 502, 'telaprevir'), ('CHEBI_63580', 'ribavirin', 545, 'ribavirin'), ('NCBITaxon_10088', 'Mus <genus>', 608, 'HCV')]
PMC5941617	5/2018	S571-PMC5941617	['the aap RECOMMENDED to treat Vitamin D deficiency administering 2000\xa0iu/day or 50,000\xa0iu/week of Vitamin D2Or D3(independent of weight) for 6\xa0week in infants (0–12\xa0months) and for 6–8\xa0weeks in children and adolescents (1–18\xa0years), SUGGESTING that Vitamin D3May be more potent than Vitamin D2[23].']	[('FUTURE_WORK', 8), ('INCOMPLETE_EVIDENCE', 232)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 97, 'vitamin D2or D3'), ('PR_000017050', 'UDP-glucuronosyltransferase 1A3', 97, 'vitamin D2or D3'), ('CHEBI_64367', 'N-ethyl-L-asparagine', 248, 'vitamin D3may'), ('CHEBI_28934', 'vitamin D2', 282, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 282, 'vitamin D2')]
